What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Enhancer Testing: Methods and Applications in Gene Regulation

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Enhancers and Enhancer Testing

What Are Enhancers?

Enhancers are cis-regulatory DNA elements that increase the transcription of target genes, often over considerable genomic distances. Unlike promoters, which are located immediately upstream of the transcription start site (TSS) and serve as the assembly point for the basal transcription machinery, enhancers function independently of orientation and can act at distances ranging from hundreds of base pairs to over a megabase. A typical enhancer is 100–1000 base pairs in length and contains clustered binding sites for sequence-specific transcription factors (TFs). These TFs, when bound, recruit coactivator complexes that modify chromatin structure and ultimately stimulate RNA polymerase II (Pol II) activity at the target promoter.

The human genome is estimated to contain hundreds of thousands to millions of putative enhancer sequences, far exceeding the approximately 20,000 protein-coding genes. This abundance reflects the combinatorial complexity of gene regulation: a single gene may be controlled by multiple enhancers, each active in a different cell type, developmental stage, or physiological condition. For example, the SHH gene is regulated by at least nine distinct enhancers, each directing expression to a specific anatomical structure during embryonic development, including the limb bud, the notochord, and the ventral forebrain.

The distinction between an enhancer and a promoter is not always absolute. Some elements, termed "bidirectional promoters" or "enhancer-promoters," exhibit characteristics of both. However, the operational definition remains useful: a promoter is defined by its position relative to the TSS and its role in initiating transcription, while an enhancer is defined by its ability to activate transcription from a distance, in an orientation-independent manner. For a more detailed comparison, see the Difference Between Enhancer and Promoter.

Why Test Enhancer Activity?

Genomic sequencing and chromatin profiling methods—such as ATAC-seq (assay for transposase-accessible chromatin with sequencing), ChIP-seq (chromatin immunoprecipitation with sequencing) for histone modifications like H3K27ac and H3K4me1, and Hi-C for chromatin conformation—can identify candidate enhancer regions with high confidence. However, these are correlative assays. They reveal where regulatory proteins bind and where chromatin is open, but they do not prove that a given sequence can actually activate transcription.

Enhancer testing is the functional validation of these candidate sequences. It answers a direct question: does this piece of DNA, when placed in a defined context, increase transcription of a reporter gene? This distinction between predicted and functional is critical. Studies have shown that only a fraction of chromatin-marked regions exhibit enhancer activity in functional assays, and the overlap between different prediction methods is often modest. Enhancer testing therefore serves as the gold standard for confirming regulatory activity, dissecting the sequence features that confer activity, and understanding how mutations in enhancer regions contribute to disease.

Core Principles of Enhancer Function

Transcription Factor Binding Sites

The fundamental unit of enhancer function is the transcription factor binding site (TFBS). A typical enhancer contains 5–15 binding sites for multiple different TFs, each recognizing a specific DNA sequence motif of 6–12 base pairs. The affinity of these interactions varies widely, with dissociation constants (Kd) ranging from nanomolar for high-affinity sites to micromolar for low-affinity sites. Importantly, enhancer activity does not simply correlate with the number of binding sites or their individual affinities; rather, it depends on the cooperative assembly of TF complexes.

Cooperative binding arises when the binding of one TF increases the affinity of a neighboring TF for its site, often through direct protein-protein interactions. For example, the enhancer of the IFN-β gene contains binding sites for NF-κB, IRF-3, and ATF-2/c-Jun. None of these factors alone can activate the promoter strongly, but when all three bind cooperatively, they form an "enhanceosome" that recruits the coactivator CBP/p300 with high efficiency. This cooperativity provides a mechanism for integrating multiple signaling inputs: the enhancer is only active when all required TFs are present and bound simultaneously.

The spacing and helical phasing of TFBSs are also critical. Because the DNA double helix has a periodicity of approximately 10.5 base pairs per turn, two TFs that bind on the same face of the DNA can interact more readily than those on opposite faces. Changing the spacing between two binding sites by half a helical turn (5 base pairs) can abolish cooperative binding and eliminate enhancer activity, even though both TFs still bind their individual sites.

Chromatin Architecture and Looping

Enhancers do not act on their target promoters through linear diffusion along the DNA. Instead, they function by physically juxtaposing with the promoter through the formation of a chromatin loop. This looping is mediated by the cohesin complex and the CTCF (CCCTC-binding factor) protein, which together organize the genome into topologically associating domains (TADs). Within a TAD, enhancer-promoter contacts are favored, while interactions across TAD boundaries are suppressed.

The loop extrusion model proposes that cohesin progressively extrudes DNA through its ring-shaped structure until it encounters CTCF-bound boundary elements, which act as insulators. This process creates dynamic loops that bring enhancers and promoters into proximity. The frequency and stability of these contacts determine the level of transcriptional activation. Single-molecule imaging studies have shown that enhancer-promoter contacts are transient, lasting only a few seconds, but occur repeatedly, allowing for bursts of transcriptional activity.

The orientation and distance independence of enhancer function is a direct consequence of looping. Because the enhancer is brought into proximity with the promoter through three-dimensional space, the linear distance between them becomes less relevant, and the orientation of the enhancer sequence relative to the promoter does not affect the geometry of the final looped complex. This is a key distinction from promoter elements, which must be in a fixed orientation relative to the TSS. For a deeper discussion of how enhancers integrate into the transcriptional machinery, see Enhancer in Transcription.

Reporter Gene Assays for Enhancer Testing

Luciferase and GFP Reporters

The classic method for enhancer testing is the reporter gene assay. In this approach, a candidate enhancer sequence is cloned upstream of a minimal promoter (typically containing only a TATA box and an initiator element) that drives expression of a reporter gene. The reporter gene encodes a protein whose activity or fluorescence can be quantified. The two most widely used reporters are firefly luciferase and green fluorescent protein (GFP).

Firefly luciferase catalyzes the oxidation of its substrate, luciferin, in the presence of ATP and molecular oxygen, producing light with a peak emission at 560 nm. The assay is performed by lysing cells, adding luciferin and ATP in excess, and measuring the resulting luminescence with a luminometer. The reaction is extremely sensitive, allowing detection of attomole quantities of enzyme. To control for transfection efficiency, a second reporter—usually Renilla luciferase, which uses a different substrate (coelenterazine) and emits at 480 nm—is co-transfected on a separate plasmid. The firefly luminescence is normalized to the Renilla luminescence, yielding a ratio that reflects enhancer activity independent of cell number or transfection efficiency.

GFP and its variants (e.g., EGFP, mCherry) offer the advantage of single-cell resolution. Rather than measuring bulk population activity, GFP reporters can be analyzed by flow cytometry or fluorescence microscopy, allowing detection of cell-to-cell variability in enhancer activity. This is particularly useful when testing enhancers that are active in only a subset of cells within a heterogeneous population. However, GFP is less sensitive than luciferase; a weak enhancer may produce fluorescence that is difficult to distinguish from autofluorescence.

A typical luciferase assay protocol proceeds as follows:

Culture cells (e.g., HeLa, HEK293T, or a cell line relevant to the enhancer's presumed activity) in a 24-well plate to 70–80% confluence.
Co-transfect 500 ng of the enhancer-reporter plasmid and 50 ng of the Renilla control plasmid using a lipid-based transfection reagent, following the manufacturer's protocol.
Incubate for 24–48 hours to allow reporter expression.
Aspirate the medium and add 100 µL of passive lysis buffer to each well.
Incubate at room temperature for 15 minutes with gentle shaking.
Transfer 20 µL of lysate to a luminometer tube or white 96-well plate.
Inject 100 µL of luciferase assay reagent (containing luciferin and ATP) and measure luminescence for 10 seconds.
Inject 100 µL of Stop & Glo reagent, which quenches the firefly reaction and provides the Renilla substrate, and measure for 10 seconds.
Calculate the firefly/Renilla ratio and compare to the empty vector control.

Transient vs. Stable Transfection

Reporter assays can be performed using either transient or stable transfection. In transient transfection, the plasmid DNA remains episomal and is not integrated into the host genome. The assay is performed 24–72 hours after transfection, before the plasmid is diluted out by cell division or degraded by nucleases. This approach is rapid and simple, but it has an important caveat: the reporter is not assembled into native chromatin. Episomal DNA is packaged into nucleosomes, but it lacks the higher-order chromatin structure, histone modifications, and nuclear positioning that characterize endogenous loci. Some enhancers, particularly those that depend on chromatin remodeling or long-range interactions, may show reduced or absent activity in transient assays.

Stable transfection overcomes some of these limitations. The reporter construct is co-transfected with a selectable marker (e.g., neomycin resistance), and cells are cultured in the presence of the selective drug (e.g., G418 at 400–800 µg/mL) for 2–3 weeks. Surviving cells have integrated the plasmid into their genome, often in tandem arrays of multiple copies. Individual clones can be isolated and characterized, or the pooled population can be used. Stable integration allows the reporter to assemble into chromatin and can reveal position effects—the influence of the surrounding genomic context on enhancer activity. However, the integration site is random, and different clones may show different levels of reporter expression due to local chromatin environment. This variability can be minimized by using site-specific integration systems, such as Flp-In or CRISPR-mediated knock-in, which target the reporter to a defined genomic locus.

Enhancer Testing in Model Organisms

Zebrafish Enhancer Assays

While cell-based reporter assays are useful for initial screening, they cannot fully recapitulate the complex environment of a developing organism. Enhancer testing in vivo provides information about tissue specificity, developmental timing, and the influence of the native chromatin context. The zebrafish (Danio rerio) is a particularly powerful model for this purpose.

Zebrafish embryos are transparent, develop externally, and can be obtained in large numbers. Enhancer testing in zebrafish typically uses a Tol2 transposon-based system. The candidate enhancer is cloned into a vector containing a minimal promoter (often the gata2 minimal promoter), a fluorescent reporter (e.g., EGFP or mCherry), and Tol2 transposon inverted repeats. The construct is co-injected with Tol2 transposase mRNA into one-cell-stage embryos. The transposase catalyzes integration of the construct into the zebrafish genome, and the embryos are then screened for fluorescence at various developmental stages.

The key advantage of the zebrafish system is the ability to assess enhancer activity in a living vertebrate with high temporal resolution. An enhancer active in the developing heart will produce fluorescence in the heart at the appropriate stage, while an enhancer active in the neural tube will produce fluorescence there. The transparency of the embryos allows direct observation without dissection. Moreover, because the Tol2 system integrates the reporter in a single copy, the fluorescence intensity provides a semi-quantitative measure of enhancer strength.

A typical zebrafish enhancer assay involves:

Clone the candidate enhancer (1–2 kb) into the Tol2 reporter vector.
Prepare a mixture containing 25 ng/µL plasmid DNA and 25 ng/µL Tol2 transposase mRNA in a solution of 0.1 M KCl and 0.05% phenol red.
Inject 1–2 nL of the mixture into the yolk of one-cell-stage embryos using a microinjection apparatus.
Incubate embryos at 28.5°C in embryo medium.
Screen for fluorescence at 24, 48, and 72 hours post-fertilization using a fluorescence stereomicroscope.
Document the spatial pattern of expression and compare between embryos and across constructs.

Mouse Transgenesis and Enhancer Traps

The mouse is the gold standard for mammalian enhancer testing. Two main approaches are used: transgenic reporter assays and enhancer trap screens.

In the transgenic approach, the candidate enhancer is cloned upstream of a minimal promoter (often the Hsp68 promoter) driving a reporter such as lacZ (encoding β-galactosidase) or GFP. The construct is then injected into the pronucleus of a fertilized mouse oocyte. The injected oocytes are implanted into pseudopregnant females, and the resulting embryos are harvested at a defined developmental stage (e.g., embryonic day 11.5) and stained for reporter activity. For lacZ, the embryos are fixed and incubated with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) at 1 mg/mL in a buffer containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl₂, and 0.01% NP-40, at 37°C for 4–16 hours. The blue precipitate reveals the spatial pattern of enhancer activity.

The transgenic approach is powerful but labor-intensive and expensive. Each construct requires the use of animals, and the integration site of the transgene can influence expression (position effects). To mitigate this, multiple independent founder lines are typically analyzed, and only those showing consistent patterns are considered reliable.

Enhancer traps are a complementary strategy. In this approach, a reporter gene with a minimal promoter but no enhancer is randomly inserted into the genome using transposon or retroviral integration. If the insertion lands near an endogenous enhancer, that enhancer can activate the reporter, producing a pattern of expression that reflects the enhancer's normal activity. The genomic location of the insertion can then be identified by sequencing. Enhancer traps have been used extensively in mice and zebrafish to discover novel enhancers and to generate reporters for specific tissues. The GENSAT (Gene Expression Nervous System Atlas) project has used this approach to create a library of BAC (bacterial artificial chromosome) transgenic mice, each expressing GFP under the control of a specific gene's regulatory regions.

High-Throughput Enhancer Testing: STARR-seq and MPRA

MPRA: Barcoded Reporters

Traditional reporter assays test one enhancer at a time. The need to test thousands of candidate enhancers—and millions of variants—has driven the development of massively parallel reporter assays (MPRAs). The core innovation of MPRA is the use of unique DNA barcodes to identify individual reporter constructs.

In a typical MPRA, thousands of candidate enhancer sequences are synthesized as oligonucleotides. Each enhancer is cloned upstream of a minimal promoter and a reporter gene (often GFP or luciferase), and each construct also contains a unique 20-nucleotide barcode in the 3' untranslated region (UTR) of the reporter mRNA. The library of constructs is then transfected into cells in a pooled format. After a defined incubation period, RNA is harvested, and the barcodes in the mRNA are amplified by RT-PCR and quantified by next-generation sequencing. The number of mRNA barcodes for each construct reflects its enhancer activity, normalized to the number of DNA barcodes in the input plasmid pool.

The key steps in an MPRA experiment are:

Library design: Synthesize oligonucleotides containing the candidate enhancer sequences, flanked by common primer binding sites for cloning.
Cloning: Pool the oligonucleotides and clone them into the MPRA vector using Gibson assembly or restriction enzyme-based methods. Each construct receives a unique barcode, which can be assigned by a separate ligation step or by using a barcode library.
Transfection: Transfect the pooled library into the relevant cell type. Use enough cells to ensure that each construct is represented by at least 100–1000 cells, to minimize sampling noise.
RNA extraction and barcode quantification: Isolate total RNA, reverse-transcribe the reporter mRNA, and amplify the barcode region by PCR with primers containing Illumina sequencing adapters.
DNA input control: In parallel, extract plasmid DNA from an aliquot of the transfected cells and amplify the barcodes to determine the representation of each construct in the input.
Sequencing and analysis: Sequence both the RNA and DNA barcode libraries. For each barcode, calculate the RNA/DNA ratio, which is proportional to enhancer activity.

MPRA has been used to test enhancer activity across entire genomes, to dissect the effects of single-nucleotide variants on enhancer function, and to identify enhancers active in specific cell types. A typical MPRA can test 10,000–100,000 candidate sequences in a single experiment.

STARR-seq: Enhancer as Its Own Reporter

STARR-seq (self-transcribing active regulatory region sequencing) takes a different approach. Instead of using a separate barcode, the enhancer sequence itself serves as the reporter. The candidate enhancer is cloned into the 3' UTR of a reporter gene. When the enhancer is active, it stimulates transcription of the reporter, and the resulting mRNA includes the enhancer sequence in its 3' UTR. By sequencing the mRNA, the enhancer sequences that drove their own transcription are identified and quantified.

The STARR-seq workflow is as follows:

Library construction: Fragment genomic DNA (or use a synthesized oligonucleotide library) and clone the fragments into the STARR-seq vector, downstream of the reporter gene's coding sequence and upstream of the polyadenylation signal.
Transfection: Transfect the library into cells. Active enhancers will increase transcription of their own locus, producing mRNA that contains the enhancer sequence.
RNA isolation and library preparation: Isolate RNA, reverse-transcribe using an oligo-dT primer (which captures the poly(A) tail), and amplify the enhancer-containing region by PCR.
Sequencing: Sequence the RNA-derived amplicons and compare to the input DNA library.
Analysis: Peaks of RNA/DNA ratio along the genome identify active enhancers.

STARR-seq has a critical advantage over MPRA: it does not require a priori knowledge of enhancer boundaries. Because the entire genomic fragment is tested, the assay can identify the minimal functional region within a larger candidate sequence. It also avoids the need for barcode assignment, simplifying the experimental design. However, STARR-seq is limited to enhancers that can function when placed in the 3' UTR, which may not be true for all enhancers. Additionally, the orientation of the enhancer in the 3' UTR is fixed, which could affect activity for orientation-dependent elements (though true enhancers should be orientation-independent).

Both MPRA and STARR-seq have been applied to study enhancer activity across the human genome in various cell lines, including K562 (erythroleukemia), HepG2 (hepatocellular carcinoma), and induced pluripotent stem cells. These studies have revealed that enhancer activity is highly context-dependent, with most enhancers showing activity in only a subset of cell types tested. For a broader perspective on the genomic features that define enhancers, see Enhancer Region and Enhancer Sequence.

Common Pitfalls in Enhancer Testing

Enhancer testing, despite its conceptual simplicity, is fraught with technical challenges that can produce misleading results. Awareness of these pitfalls is essential for interpreting data and designing robust experiments.

1. Minimal promoter choice. The minimal promoter used in reporter assays is not inert. Different minimal promoters (e.g., Hsp68, gata2, SV40, TK) have different basal activities and respond differently to enhancer signals. An enhancer that activates one minimal promoter may be inactive with another. This is particularly problematic for MPRA and STARR-seq, where a single promoter is used for all constructs. The choice of promoter can therefore bias the results toward enhancers that are compatible with that specific promoter context.

2. Position effects in stable lines. When reporter constructs are integrated into the genome, the surrounding chromatin can influence expression. An enhancer that is active in transient transfection may be silenced when integrated near heterochromatin, or conversely, an inactive sequence may appear active if it integrates near an endogenous enhancer. This is why multiple independent lines or clones must be analyzed, and why transient assays, despite their limitations, remain useful for initial screening.

3. Cryptic promoter activity. Some enhancer sequences contain internal promoter elements that can drive transcription independently of the minimal promoter. In reporter assays, this can produce false-positive results, as the "enhancer" is actually acting as a promoter. This is a particular concern for STARR-seq, where the enhancer sequence itself is transcribed. To control for this, constructs with the enhancer in the reverse orientation or with the minimal promoter deleted should be tested.

4. Copy number and titration effects. In transient transfection, the amount of plasmid DNA delivered can affect the results. High copy numbers can saturate the transcriptional machinery, masking differences between strong and weak enhancers. Conversely, low copy numbers may produce signals below the detection threshold. It is essential to titrate the amount of reporter plasmid and to include a titration series of a known strong enhancer as a positive control.

5. Cell type mismatch. Enhancer activity is highly cell-type-specific. An enhancer that is active in the liver will not be active in HeLa cells. Testing an enhancer in an inappropriate cell type will produce a false-negative result. The cell type for testing should be chosen based on the known or predicted expression pattern of the target gene, or a panel of cell types should be used.

6. Fragment size and boundary effects. The activity of an enhancer can depend on its flanking sequences. A fragment that is too short may lack critical binding sites, while a fragment that is too long may include repressor elements. The choice of fragment boundaries can therefore determine the outcome. In high-throughput assays, this is a systematic issue: the results are only as good as the fragment design.

7. Technical noise in high-throughput assays. MPRA and STARR-seq are subject to substantial technical noise. The number of cells transfected, the efficiency of RNA extraction, and the depth of sequencing all contribute to variability. Replicates are essential, and the analysis must account for the fact that the RNA/DNA ratio is a noisy measurement. Low-expressing constructs are particularly affected, and many apparent "enhancers" identified in a single experiment may not replicate.

Frequently Asked Questions

What is the most common enhancer testing method?

The most common method is the transient transfection reporter assay using firefly luciferase. A candidate enhancer is cloned upstream of a minimal promoter driving luciferase, and the construct is transfected into cells alongside a Renilla luciferase control. After 24–48 hours, the cells are lysed, and the ratio of firefly to Renilla luminescence is measured. This method is widely used because it is rapid, inexpensive, and quantitative, making it suitable for testing individual enhancers and for comparing the activities of multiple variants.

How do you test enhancer activity in vivo?

In vivo enhancer testing is performed in model organisms, most commonly zebrafish and mice. In zebrafish, the enhancer is cloned into a Tol2 transposon vector with a minimal promoter and a fluorescent reporter, and the construct is injected into one-cell-stage embryos along with transposase mRNA. The embryos are then examined for fluorescence at various developmental stages. In mice, the enhancer is cloned upstream of a minimal promoter driving lacZ or GFP, and the construct is injected into fertilized oocytes. The resulting embryos are harvested and stained to reveal the spatial pattern of reporter expression.

What is MPRA and how does it work?

MPRA (massively parallel reporter assay) is a high-throughput method for testing thousands of enhancer sequences simultaneously. Each candidate enhancer is cloned upstream of a minimal promoter and a reporter gene, and each construct carries a unique DNA barcode in the 3' UTR of the reporter mRNA. The constructs are pooled and transfected into cells. After incubation, RNA is harvested, and the barcodes in the mRNA are amplified and sequenced. The number of mRNA barcodes for each construct, normalized to the number of DNA barcodes in the input, reflects the enhancer's activity.

What is STARR-seq?

STARR-seq (self-transcribing active regulatory region sequencing) is a high-throughput enhancer assay in which the candidate enhancer sequence itself serves as the reporter. The enhancer is cloned into the 3' UTR of a reporter gene. When the enhancer is active, it stimulates transcription, and the resulting mRNA contains the enhancer sequence. By sequencing the mRNA, the enhancer sequences that drove their own transcription are identified. The RNA/DNA ratio for each genomic region indicates enhancer activity.

Why are enhancer testing results sometimes inconsistent?

Inconsistency arises from several sources. First, enhancer activity is context-dependent: an enhancer may be active in one cell type but not another, and the minimal promoter used in the assay can influence the result. Second, the genomic context matters—an enhancer tested as an episome in transient transfection may behave differently when integrated into chromatin. Third, the choice of fragment boundaries can include or exclude critical regulatory elements. Finally, technical noise, particularly in high-throughput assays, can produce false positives and false negatives that do not replicate across experiments.

Can enhancer testing be done in silico?

In silico methods can predict enhancer activity but cannot replace functional testing. Computational tools use sequence features (e.g., TFBS motifs, conservation, chromatin marks) and machine learning to score candidate enhancers. These predictions are useful for prioritizing candidates for experimental testing, but they are imperfect. The correlation between predicted and measured activity is typically moderate, and many predicted enhancers fail functional assays while some functional enhancers are not predicted. In silico analysis is best used as a filter to reduce the number of candidates for experimental validation.

What are common pitfalls in enhancer testing?

Common pitfalls include: using an inappropriate minimal promoter that biases the results; testing enhancers in the wrong cell type; failing to control for cryptic promoter activity within the enhancer sequence; position effects in stable lines; and technical noise in high-throughput assays. Additionally, the choice of fragment boundaries can determine the outcome, and copy number effects in transient transfection can mask differences between strong and weak enhancers. Careful experimental design, including appropriate positive and negative controls and multiple replicates, is essential for reliable results.

Key Takeaways

Enhancers are cis-regulatory DNA elements that activate transcription from a distance, in an orientation-independent manner, by recruiting transcription factors and looping to the target promoter.
Enhancer testing is the functional validation of candidate regulatory sequences, distinguishing active enhancers from those predicted by chromatin marks or sequence features alone.
The classic reporter gene assay uses firefly luciferase or GFP under the control of a minimal promoter, with normalization to a co-transfected control to correct for transfection efficiency.
In vivo testing in zebrafish and mice provides information about tissue specificity and developmental timing that cannot be obtained from cell-based assays.
MPRA and STARR-seq enable high-throughput testing of thousands to millions of enhancer sequences in a single experiment, using DNA barcodes or the enhancer sequence itself as the reporter.
Enhancer activity is highly context-dependent, and results can vary with cell type, minimal promoter choice, genomic integration site, and fragment boundaries.
Computational prediction of enhancer activity is useful for prioritization but cannot replace functional testing, which remains the gold standard for defining enhancer activity.